D1 Receptor Allosteric Modulators for Selective Dopamine Signaling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Developing orally bioavailable small molecules that selectively target D1 receptors has been challenging due to high homology in ligand binding sites between dopamine receptor subtypes, leading to limited clinical use and side effects such as dyskinesia and hypotension in existing D1 agonists.
Innovation Solution
Designing D1 Positive Allosteric Modulators (PAMs) that potentiate the effect of D1 agonists or endogenous ligands through an allosteric mechanism, reducing direct activation and associated side effects by targeting distinct sites on the receptor.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If D1 agonists are developed to treat diseases related to D1 receptors, then therapeutic efficacy is improved, but side effects such as dyskinesia and hypotension increase
Solution Approach 1:
The invention segments the receptor interaction into two distinct parts: the orthosteric site for endogenous ligand binding and an allosteric site for the modulator binding. This segmentation allows the compound to modulate receptor activity indirectly through conformational changes rather than direct activation, reducing side effects while maintaining therapeutic efficacy.
Solution Approach 2:
The allosteric modulator acts as an intermediary that indirectly influences receptor activation. Instead of directly binding to the orthosteric site and causing activation, the modulator binds to a distinct allosteric site and induces conformational changes that modulate the receptor's response to endogenous ligands, thereby reducing direct activation and associated side effects.
2Reliability
If D1 agonists are designed to target D1 receptors selectively, then subtype selectivity is improved, but difficulty in achieving sufficient selectivity increases due to high homology in ligand binding sites
Solution Approach 1:
The invention transitions from targeting the conserved orthosteric binding site to targeting an allosteric site that exhibits greater divergence between receptor subtypes. By binding to the allosteric site, the modulator exploits structural differences in this region to achieve subtype selectivity, effectively adding a new dimensional approach to overcoming the homology problem.
3Duration of action of stationary object
If D1 agonists are administered continuously to maintain therapeutic effect, then duration of action is improved, but desensitization and tolerance increase
Solution Approach 1:
The allosteric modulator enables periodic or conditional activation of the receptor based on endogenous ligand presence. Rather than continuously activating the receptor, the modulator potentiates receptor response only when endogenous ligands are present, creating a more physiological pattern of activation that reduces desensitization and tolerance development while maintaining therapeutic benefits.
Data Source
AI summary
The present invention relates to tetrahydroisoquinolinyl derivatives of formula (I), which are Positive Allosteric Modulators of D1 and accordingly of benefit as pharmaceutical agents for the treatment of diseases in which D1 receptors play a role.